Journal Club 2025

Want to be a Journal Club presenter?

The call for August-December 2025 session speakers is currently open!

Find out more and apply here!

Next HOPA Journal Club

Tuesday, May 13, 2025 at 2 p.m. Central Time

Listen to critical evaluations of hematology/oncology pharmacy publications presented by PGY2 Oncology Residents.

Click here to register for May's Journal Club!

Durvalumab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Hanh Tran, PharmD, PGY2 Oncology Pharmacy Resident

Wellstar MCG Health, Augusta, GA

Article:

Durvalumab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

Yong Jun "Eric" Bae, PharmD, PGY2 Oncology Pharmacy Resident

Dana-Farber Cancer Institute, Boston, MA

Article:

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

Reserve your spot for May's Journal Club!

Featured Articles

HOPA Members

HOPA President Combines People-First Approach with Oncology Pharmacy Expertise

April 11, 2025

HOPA officially welcomed Dr. Robert Mancini as its President at its annual conference in Portland, Oregon on April 11, 2025.

Tools and Resources

Pharmacist's Application to Practice: Mirdametinib

April 04, 2025

Ramsey Shane, PharmD, MPH, PGY1 Pharmacy Resident, and Rebecca Pokorny, PharmD, BCPS, BCOP, Clinical Pharmacist Specialist Neuro-Oncology - both from Vanderbilt University Medical Center, Nashville, TN - write about mirdametinib (Gomekli).

Tools and Resources

Pharmacist's Application to Practice: Ensartinib

March 17, 2025

Savannah Young, PharmD, PGY1 Pharmacy Resident, from Sarasota Memorial Hospital, Sarasota, FL, and Kiera Roubal, PharmD, BCOP, Clinical Oncology Pharmacist Specialist, from Medical University of South Carolina, Charleston, SC, write about ensartinib.